Instrument Inactif

Communiqués CTI BioPharma Corp.

Actions

CTIC

US12648L6011

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Sobi publishes Q3 2023 report: Strong revenue and solid performance	30/10/23	AQ
Sobi completes acquisition of CTI BioPharma Corp.	27/06/23	AQ
Sobi successfully completes tender offer for all outstanding shares of common stock of CTI BioPharma Corp.	24/06/23	PR
Sobi successfully completes tender offer for all outstanding shares of common stock of CTI BioPharma Corp.	24/06/23	AQ
CTI BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CTI BioPharma Corp. - CTIC	06/06/23	BU
CTI BioPharma Announces Cancellation of its 2023 Annual Meeting of Stockholders	30/05/23	PR
Sobi commences tender offer for all outstanding shares of common stock of CTI BioPharma Corp.	25/05/23	AQ
CTI BioPharma: Q1 Earnings Snapshot	16/05/23	AQ
$1.7b acquisition to develop rare haematology therapy	12/05/23	AQ
CTI BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CTI BioPharma Corp. - CTIC	11/05/23	BU
Shareholder Alert: Ademi LLP investigates whether CTI BioPharma Corp. has obtained a Fair Price in its transaction with Sobi	10/05/23	PR
CTIC STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of CTI BioPharma Corp. Is Fair to Shareholders	10/05/23	BU
CTI BioPharma : TENDER AND SUPPORT AGREEMENT - Form 8-K	10/05/23	PU
CTI BIOPHARMA CORP : Entry into a Material Definitive Agreement, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	10/05/23	AQ
Sobi to Acquire CTI BioPharma	10/05/23	PR
Investor supports Sobi's tender offer for CTI BioPharma and undertakes to subscribe for its pro rata share in Sobi's rights issue	10/05/23	AQ
Sobi to acquire CTI BioPharma Corp. enhancing Sobi's position in rare haematology	10/05/23	AQ
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	05/05/23	PR
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	02/05/23	PR
CTI BioPharma To Report First Quarter 2023 Financial Results and Provide Corporate Update on Thursday, May 11, 2023	01/05/23	PR

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués CTI BioPharma Corp.

Actions

CTIC

US12648L6011

Communiqués

Filtres